CSL Behring

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (April 2014) (Learn how and when to remove this message) This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (December 2018) (Learn how and when to remove this message) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "CSL Behring" – news · newspapers · books · scholar · JSTOR (February 2021) (Learn how and when to remove this message) (Learn how and when to remove this message)

CSL Behring LLC

Traded as	ASX: CSL
Industry	Biopharmaceutical, health care
Headquarters	King of Prussia, Pennsylvania
Key people	Paul McKenzie, CEO and Managing Director of CSL Limited
Number of employees	27,000+[1]
Parent	CSL Limited
Website	www.cslbehring.com

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products.^[2] The company is a combination of Behringwerke, founded in 1904 in Marburg, Germany by Emil von Behring, and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia, as well as other companies acquired since 2004.